Gut-brain Axis, Brain Function, and Behaviour.

Not Applicable

• Conditions: Emotion; Prebiotics; Anxiety; Decision Making; Humans; Magnetic Resonance Imaging; Cortisol
• Interventions: Dietary Supplement: Prebiotics; Dietary Supplement: Maltodextrin (placebo)

• Registration Number: NCT03554694
• Lead Sponsor: University of Oxford

Brief Summary

The aim is to test if dietary supplementation with prebiotics reduces measures of anxiety in healthy human participants with high self-reported levels of anxiety. Study will test for an effect on behavioural, neuroendocrine and brain imaging markers of anxiety.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2018-05
• Study Start: 2018-05-06
• Study First Submitted: 2018-05-09
• Study First Submitted QC: 2018-06-11
• Last Update Submitted: 2018-06-11
• Study First Posted: 2018-06-13
• Last Update Posted: 2018-06-13
• Primary Completion: 2019-12
• Study Completion: 2019-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Trait anxiety levels > 40 on STAI trait inventory
• Participant is willing and able to give informed consent for participation in the study
• Not currently taking any psychoactive medications

Read More

Exclusion Criteria

• Pregnant participants
• No contraindications to prebiotic administration
• Antibiotic, probiotics and/or prebiotic treatment in at least the two previous months.
• Participants who are taking any other food supplements that, in the opinion of the Investigators, may affect the results.
• Participants who are taking any medications that, in the opinion of the Investigators, may affect the results.
• Any significant change in diet which, at the discretion of the Investigators, may affect the results.
• Participants who have recently participated in another research trial which, at the discretion of the Investigators, may affect the results.
• A history of dementia, traumatic brain injury or stroke.
• Anyone who is unable to perform the behavioural tasks.
• Current use of any psychoactive medication.
• Current use of psychological treatment.
• Anyone who does not have adequate understanding of English, sufficient to give informed consent.
• Any person who has a history of drug abuse or a previous history of a neurological, or has a history of neurosurgical procedure is excluded as they may be at increased risk of epilepsy and data collected may be influenced by their condition.
• Anyone with any metal implants or implantable device would be excluded from any brain imaging studies as indicated by the MRI safety screening form.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Start with prebiotics	Prebiotics	Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
Start with placebo	Maltodextrin (placebo)	Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.

Primary Outcome Measures

Name	Time	Method
Brain imaging (BOLD fMRI activity) in amygdala and cortical regions	Brain imaging will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).	Brain imaging (BOLD fMRI activity) in amygdala and cortical regions Will provide neural measures of threat reactivity. We predict decreased amygdala and/or increased parietal-prefrontal brain activity after prebiotics compared to placebo, indicating an anxiolytic-like profile (fearful -neutral face trials in the low load condition) (as in Bishop et al, 2007 and Ironside et al, 2017)
Cortisol awakening response (CAR)	Cortisol awakening responses will be measured at the end of the first intervention phase (4-6 weeks after study entry) and at the end of the second intervention phase (11-15 weeks post study entry).	CAR, a marker of stress responsivity, should be decreased after taking prebiotics compared to placebo (as previously found in non-anxious participants in Schmidt et al., 2015, Psychopharmacology)

Secondary Outcome Measures

Name	Time	Method
Changes in gut microbiome	Changes in the microbiome will be measure using a single stool/faecal sample at four time points: baseline (0 weeks), following first intervention (4-6 weeks), following washout (7-9 weeks), and following the second intervention (11-15 weeks).	Availability of specific bacteria in microbiome will change as function of prebiotics and not during placebo. The change will be measured at the start of each intervention compared to the end of each intervention

Trial Locations

Locations (1)

University of Oxford; 🇬🇧 Oxford, Oxfordshire, United Kingdom